Drugs / Talniflumate
Talniflumate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06777537 | Jun 2025 → Dec 2030 expected | breast cancer | Shandong University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT02384928 Comparator | Sep 2015 → Jan 2017 | lumbar disk disease, sciatica | Jaseng Medical Foundation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Talniflumate | “talniflumate (Drug class: NSAIDs)” NCT02384928 ↗ |
| Known as | BA 7602-06 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1081506 ↗ |
| Known as | Somalgen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1081506 ↗ |
| Known as | Talniflumato | ChEMBL registry synonym — accepted as the source's own label CHEMBL1081506 ↗ |
| Modality | Small molecule | — CHEMBL1081506 ↗ |